Galactomannan C

Drug Profile

Galactomannan C

Alternative Names: Carbohydrate polymer; DAVANAT®; GM-CT-01

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pro-Pharmaceuticals
  • Developer Galectin Therapeutics; Icahn School of Medicine at Mount Sinai; Pro-Pharmaceuticals
  • Class Antineoplastics; Mannans; Polymers
  • Mechanism of Action Galectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Colorectal cancer

Highest Development Phases

  • No development reported Malignant melanoma
  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Hepatic fibrosis

Most Recent Events

  • 10 Aug 2017 Discontinued - Phase-II for Biliary cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV)
  • 10 Aug 2017 Galectin Therapeutics withdraws a phase II trial prior to enrolment due to financing and re-organisation in Biliary cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT00386516)
  • 30 May 2017 Discontinued - Preclinical for Hepatic fibrosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top